Northern Trust Corp boosted its holdings in shares of DocGo Inc. (NASDAQ:DCGO - Free Report) by 24.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,606,139 shares of the company's stock after buying an additional 320,133 shares during the quarter. Northern Trust Corp owned 1.57% of DocGo worth $6,810,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its stake in DocGo by 151.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 109,855 shares of the company's stock worth $365,000 after acquiring an additional 66,097 shares in the last quarter. Matrix Asset Advisors Inc. NY acquired a new position in DocGo during the fourth quarter worth about $424,000. Barclays PLC raised its position in DocGo by 14.5% during the fourth quarter. Barclays PLC now owns 154,456 shares of the company's stock worth $655,000 after acquiring an additional 19,533 shares during the last quarter. Vanguard Group Inc. raised its position in shares of DocGo by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 5,014,375 shares of the company's stock valued at $21,261,000 after buying an additional 14,454 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of DocGo by 4.5% in the fourth quarter. Rhumbline Advisers now owns 142,762 shares of the company's stock valued at $605,000 after buying an additional 6,204 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts have issued reports on DCGO shares. Canaccord Genuity Group reiterated a "hold" rating and set a $1.45 price objective (down from $5.00) on shares of DocGo in a research note on Monday, May 12th. Deutsche Bank Aktiengesellschaft cut shares of DocGo from a "buy" rating to a "hold" rating and lowered their target price for the company from $5.00 to $2.85 in a research note on Friday, February 28th. Needham & Company LLC reduced their price objective on shares of DocGo from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Stifel Nicolaus decreased their target price on shares of DocGo from $6.50 to $5.50 and set a "buy" rating for the company in a report on Friday, February 28th. Finally, BTIG Research cut shares of DocGo from a "buy" rating to a "neutral" rating in a report on Friday, May 9th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $3.56.
Get Our Latest Analysis on DocGo
DocGo Price Performance
DocGo stock remained flat at $1.34 during trading hours on Friday. 708,692 shares of the company's stock were exchanged, compared to its average volume of 804,273. DocGo Inc. has a 52 week low of $1.23 and a 52 week high of $5.68. The company has a market cap of $136.66 million, a price-to-earnings ratio of 4.79, a price-to-earnings-growth ratio of 14.16 and a beta of 1.14. The business's fifty day moving average price is $2.21 and its 200 day moving average price is $3.54.
DocGo (NASDAQ:DCGO - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The company had revenue of $96.03 million for the quarter, compared to analyst estimates of $104.25 million. DocGo had a return on equity of 8.90% and a net margin of 4.35%. On average, analysts forecast that DocGo Inc. will post 0.25 EPS for the current fiscal year.
About DocGo
(
Free Report)
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
Further Reading

Before you consider DocGo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.
While DocGo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.